Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.32
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsZing Health GnRH Agonist Prior Auth | OpenPayer
    Ask Trek AI about this page
    CurrentZing HealthPolicy 4257-D

    Medicare Part B Step Therapy Gonadotropin Releasing Hormone Agonists

    Customize your policy alerts

    Sign up for zing_health Policy 4257-D alerts

    Get alerted when Policy 4257-D changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Medicare Part B coverage of gonadotropin-releasing hormone agonists for prostate cancer; Eligard is preferred, and non-preferred products require a qualifying clinical exception through prior authorization.

    Policy Summary
    PayerZing Health
    PolicyMedicare Part B Step Therapy Gonadotropin Releasing Hormone Agonists
    Policy CodePolicy 4257-D
    Change TypeNo material change
    Effective DateN/A
    Next Review DateN/A
    Key ActionUse preferred Eligard unless the member qualifies for a non-preferred product exception.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    1Preferred product
    4Non-preferred products
    2Exception pathways
    365 daysPrior-treatment lookback

    Non-Preferred Product Exceptions

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Non-preferred product exception criteria

    Coverage for a non-preferred product is provided when either of the following criteria is met:

    Qualifying non-preferred product exception

    • Recent prior non-preferred treatment: Member has received treatment with a non-preferred product in the past 365 days.past 365 days
    • Hypersensitivity to preferred product: Member has a documented hypersensitivity to the preferred product.

    Authorization and Documentation Requirements

    Prior Authorization

    Exception Review for Non-Preferred Products

    Submit a prior authorization request for any non-preferred gonadotropin-releasing hormone agonist. The review will assess clinical circumstances that would exclude use of the preferred product and may consider previous treatment with a non-preferred product.

    • This program applies to all members requesting treatment with a non-preferred product.
    • Step therapy applies in addition to any applicable NCD, LCD, and Medicare Part B utilization management programs.
    Step Therapy

    Preferred-Product Step Requirement

    Eligard (leuprolide acetate) is the preferred product. A non-preferred product requires a qualifying exception through prior authorization before coverage can be provided.

    • Non-preferred products: Camcevi, Lupron Depot, Trelstar, and Zoladex.
    • Preferred products may still require a clinical prior authorization review.
    Documentation Required

    Documented Preferred-Product Hypersensitivity

    When requesting the hypersensitivity exception pathway, document the member’s hypersensitivity to the preferred product, Eligard (leuprolide acetate).

    • The hypersensitivity must be documented in the prior authorization request.
    Documentation Required

    Recent Non-Preferred Treatment History

    When requesting the prior-use exception pathway, document that the member received treatment with a non-preferred product within the past 365 days.

    • Include the non-preferred product and treatment history supporting use within the 365-day period.
    Denial Risk

    Non-Preferred Product Lacks Qualifying Exception

    Coverage for a non-preferred product may be denied when neither qualifying exception pathway is met. The request must establish either documented hypersensitivity to Eligard or treatment with a non-preferred product within the past 365 days.

    • Qualifying exception pathways: documented hypersensitivity to the preferred product or non-preferred treatment within the past 365 days.

    Policy Scope

    This policy applies to Medicare Part B requests for gonadotropin-releasing hormone agonists used to treat prostate cancer. Eligard (leuprolide acetate) is the preferred product; non-preferred products are subject to step therapy and may be covered through a qualifying clinical exception reviewed through prior authorization.

    Non-Preferred Product Exception Pathways

    Initial non-preferred product exception

    Coverage for a non-preferred product is provided when either of the following criteria is met:

    Non-preferred product exception

    • Prior non-preferred treatment: Member has received treatment with a non-preferred product in the past 365 days.past 365 days
    • Preferred-product hypersensitivity: Member has a documented hypersensitivity to the preferred product.

    Preferred Product Requirement

    StepPreferred product requirementNon-preferred product exception
    1Use preferred Eligard (leuprolide acetate).A non-preferred product is covered when the member has received treatment with a non-preferred product within the past 365 days or has documented hypersensitivity to the preferred product.
    Policy Summary
    PayerZing Health
    PolicyMedicare Part B Step Therapy Gonadotropin Releasing Hormone Agonists
    Policy CodePolicy 4257-D
    Change TypeNo material change
    Effective DateN/A
    Next Review DateN/A
    Key ActionUse preferred Eligard unless the member qualifies for a non-preferred product exception.
    SourceLink
    On This Page
    Non-Preferred Product ExceptionsAuthorization and Documentation RequirementsPolicy ScopeNon-Preferred Product Exception PathwaysPreferred Product Requirement